Creating Efficiencies in Drug Discovery and Development Using Artificial Intelligence
Priya Mannan, Associate General Counsel, Novartis Institutes for Biomedical Research
The recent growth of machine learning applications using artificial intelligence (AI), ranging from drug discovery to improvements in patient care, has coincided with increased investments from pharmaceutical and technology companies. Subsequently, there has been a sharp increase in the number of start-ups in this space along with heightened expectations regarding the implications of AI in the health care industry. Given the strict regulations pertaining to drug development and commercial marketing, there are questions as to whether AI can operate within the contours of existing laws or would require novel legal frameworks. This article makes an effort to address those emerging questions.
Read full paper
Subscribe to the IICJ